Triumph Capital Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
Other funds holding NVS
Triumph Capital Management's NVS Position: Q2 2026 in Review
Triumph Capital Management increased its Novartis (NVS) stake by 1.3% in Q2 2026, buying an estimated $1.5K and bringing the position to 752 shares worth $118K. The position accounts for 0.02% of the portfolio, ranked #455.
Triumph Capital Management first reported a position in NVS in Q4 2025 and has held it in 3 quarters since. 1,624 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Triumph Capital Management held 752 shares of Novartis worth $118K as of Q2 2026.
- Triumph Capital Management bought 10 Novartis shares in Q2 2026, an estimated $1.5K.
- Novartis made up 0.02% of Triumph Capital Management's portfolio in Q2 2026, its #455 holding.
- Triumph Capital Management first reported a position in Novartis in Q4 2025 and has held it in 3 quarters since.
- 1,624 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.